CWBR Cohbar Inc

CohBar to Announce 2018 Third Quarter Financial Results and Host Conference Call on November 14, 2018

CohBar to Announce 2018 Third Quarter Financial Results and Host Conference Call on November 14, 2018

MENLO PARK, Calif., Oct. 31, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that it will release its third quarter 2018 financial results after the market closes on Wednesday, November 14, 2018, followed by a conference call on which the company’s management will discuss the results and provide a company update.

Details for the Conference Call:

Date: November 14, 2018

Time: 2:00 p.m. (Pacific Time)

Conference Audio

  • Dial-in U.S. and Canada: (888) 394-8218
  • Dial-in International: (323) 701-0225
  • Conference ID No.: 1659879

We kindly request that you call into the conference audio approximately 10 minutes before the start time so that we can begin promptly.

An audio replay of the call will be available beginning at 5:00 p.m. Pacific Time on November 14, 2018, through 9:00 p.m. Pacific Time on December 5, 2018. To access the recording please dial (844) 512-2921 in the U.S. and Canada, or (412) 317-6671 internationally, and reference Conference ID No. 1659879. The audio replay will also be available at from November 14, through December 5, 2018.

About CohBar

CohBar is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar’s founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar’s efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases with underlying metabolic dysfunction, including nonalcoholic steatohepatitis (NASH), obesity, Type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases. To date, the company and its founders have discovered more than 100 MDPs. For additional company information, please visit .

Investor and Media Contacts:

Jeff Biunno, CFO

CohBar, Inc.

(650) 446-7888, Option 3

Joyce Allaire

LifeSci Advisors, LLC

 

EN
31/10/2018

Underlying

CWBRCohbar Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cohbar Inc

 PRESS RELEASE
Free
CWBR COHBAR INC

CohBar Reports Second Quarter 2023 Financial Results

CohBar Reports Second Quarter 2023 Financial Results MENLO PARK, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) today reported its financial results and highlights for the second quarter ended June 30, 2023. Second Quarter 2023 Summary and Financial Results Entered into Definitive Merger Agreement with Morphogenesis: In May 2023, CohBar announced that the company entered into a definitive merger agreement with a privately held biotechnology company, Morphogenesis, Inc. (“Morphogenesis”), for an all-stock transaction to advance a late-stage oncology pipeline. The c...

August 14, 2023 1 EN
 PRESS RELEASE
Free
CWBR COHBAR INC

Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Ph...

Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5 of 7 (71%) of patients achieved durable systemic anti-tumor responses following IFx-Hu2.0 therapy and rechallenge with an immune checkpoint inhibitor (ICI) in patients who exhibited primary resistance to ICIs Translational biomarker data underscores ...

June 5, 2023 1 EN
 PRESS RELEASE
Free
CWBR COHBAR INC

Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract f...

Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting TAMPA, Fla. and MENLO PARK, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. (“Morphogenesis”), a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies, and CohBar, Inc. (NASDAQ: CWBR) (“CohBar”), today announced that Morphogenesis’ abstract has been accepted for poster prese...

May 30, 2023 1 EN
 PRESS RELEASE
Free
CWBR COHBAR INC

CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agre...

CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy Combined company will operate under the name “TuHURA Biosciences, Inc.” and advance a personalized cancer vaccine platform and preclinical tumor microenvironment modulatorsLead asset, IFx-Hu2.0, expected to enter Phase 2/3 registration trial as first-line treatment for Merkel Cell Carcinoma in early 2024$15 million PIPE financing to close concurrent with the closing of the proposed merge...

May 23, 2023 1 EN
 PRESS RELEASE
Free
CWBR COHBAR INC

CohBar Reports Third Quarter 2022 Financial Results and Highlights Rec...

CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress Conference call and webcast today at 5:00 p.m. ET, November 8, 2022 MENLO PARK, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the third quarter ended September 30, 2022 and highlighted recent corporate progress. “I’m plea...

November 8, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch